BCL2L1
ENSG00000171552
Target class
Ion channel
Chromosome
20
Approved drugs
0
Clinical candidates (approved and in development)
2
- Approved drugs
- 0
- Clinical candidates (approved and in development)
- 2
- Chemical probe available
- Yes
- Target name
- BCL2L1
- Gene name
- BCL2 like 1
- Gene symbol
- BCL2L1
- Protein name
- Bcl-2-like protein 1 (Bcl2-L-1) (Apoptosis regulator Bcl-X)
- BCLX
- BCL2L
- Bcl-X
- bcl-xL
- bcl-xS
- PPP1R52
- Gene biotype
- Protein coding
- Gene family
- Protein phosphatase 1 regulatory subunits|BCL2 family
- Target class
- Ion channel
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 185.28
- Tissue specificity (Gini)
- 0.237
- Tissue specificity (tau)
- 0.537
- KEGG gene identifiers
- hsa:598
- Protein interaction confidence
- 0.855365
- Protein interaction partners
- 137
- R-HSA-111453
- R-HSA-6785807
- R-HSA-844455
- R-HSA-9648002
- R-HSA-9692913
- R-HSA-9702518
- R-HSA-9818030
- End position
- 31723989
- Start position
- 31664452
- Chromosome
- 20
- Strand
- Reverse
- [Isoform Bcl-X(L)]: Mitochondrion inner membrane . Mitochondrion outer membrane . Mitochondrion matrix . Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane . Cytoplasm, cytosol . Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Nucleus membrane
- Single-pass membrane protein
- Cytoplasmic side . Note=After neuronal stimulation, translocates from cytosol to synaptic vesicle and mitochondrion membrane in a calmodulin-dependent manner (By similarity). Localizes to the centrosome when phosphorylated at Ser-49. .
- Acrosome
- Mitochondria
- Tissue specificity (tau)
- 0.536887
- Expression inequality (Gini)
- 0.236552
Expression in transcripts per million
- Artery - Aorta
- 185.28
- Lung
- 180.34
- Whole Blood
- 176.29
- Nerve - Tibial
- 157.35
- Artery - Coronary
- 150.73
Expression in transcripts per million
- Artery - Aorta185.28
- Lung180.34
- Whole Blood176.29
- Nerve - Tibial157.35
- Artery - Coronary150.73
- Artery - Tibial147.09
- Cells - Cultured fibroblasts143.72
- Adipose - Subcutaneous127.47
- Breast - Mammary Tissue119.02
- Kidney - Medulla114.17
- Brain - Cerebellum113.77
- Brain - Cerebellar Hemisphere113.72
- Thyroid110.4
- Testis106.7
- Prostate103.84
- Skin - Sun Exposed (Lower leg)101.13
- Esophagus - Mucosa98.73
- Minor Salivary Gland96.26
- Esophagus - Muscularis95.22
- Adipose - Visceral (Omentum)92.81
- Vagina92.33
- Kidney - Cortex92.14
- Pituitary91.33
- Spleen88.67
- Cervix - Endocervix86.97
And 29 more, listed on the interactive page.
- GO:0001836
- GO:0008637
- GO:0032465
- GO:0034097
- GO:0043066
- GO:0046902
- GO:0051607
- GO:0051881
- GO:0090201
- GO:1900118
- GO:1902042
- GO:1902230
- GO:1902236
- GO:1903077
- GO:2001240
- GO:2001243
- GO:0005737
- GO:0005739
- GO:0005741
- GO:0005813
- GO:0005829
- GO:0097136
- GO:0005515
- GO:0019901
- GO:0042802
- GO:0051434
Related records
Trials (757)
- 8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia
- A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
- A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma
- A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
- A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
- A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction
- a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia
- A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in Adults With Non-Hodgkin's Lymphoma
- A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
- A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
- A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies
- A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia
- A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
- A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients
- A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL
- A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
- A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy
Drugs (7)
- ABT 737
- Foselutoclax
- Navitoclax Apoptosis regulator Bcl-X inhibitor
- Navitoclax dihydrochloride Apoptosis regulator Bcl-X inhibitor
- Obatoclax Apoptosis regulator Bcl-X inhibitor
- Obatoclax mesylate Apoptosis regulator Bcl-X inhibitor
- Venetoclax